Multi-center, open-label, long-term study of OraVescent fentanyl citrate [fentanyl] for the treatment of breakthrough pain in opioid tolerant cancer patients
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2012
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Registrational
- Sponsors Cephalon
- 27 Jun 2012 Drug company (Teva Pharmaceutical Industries) added as reported by ClinicalTrials.gov.
- 25 May 2007 Status changed from recruiting to completed
- 18 Oct 2005 New trial record.